High throughput mRNA sequencing reveals potential therapeutic targets of Si-Ni-San in the pons for a stress-induced depression model

被引:0
作者
Li, Junling [1 ]
Zhang, Yan [2 ]
Li, Te [1 ]
Nie, Binbin [3 ]
Qi, Fang [1 ]
Chen, Qijun [1 ]
Chen, Tianxing [1 ]
Liu, Yuhang [1 ]
Li, Gaifen [4 ]
Li, Yubo [4 ]
机构
[1] Capital Med Univ, Sch Tradit Chinese Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Tradit Chinese Med, Beijing, Peoples R China
[3] Chinese Acad Sci, Inst High Energy Phys, Key Lab Nucl Analyt Tech, Beijing, Peoples R China
[4] China Acad Chinese Med Sci, Inst Basic Theory Tradit Chinese Med, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
CUMS; Si-Ni-San; pons; antidepressant mechanism; RNA-seq; fMRI; EXPRESSION; MECHANISM; BRAIN;
D O I
10.3389/fphar.2024.1383624
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: An accumulating body of research indicates that the pons is related to the occurrence of depression. Si-Ni-San (SNS) is a well-known Chinese herbal formula that is used to treat depression. Chinese herbal formulae have multiple therapeutic characteristics. Although it has been proven that SNS can exert antidepressant effects by improving changes in the limbic system, it is currently unclear whether SNS has therapeutic targets in the pons. This study aimed to explore the therapeutic targets of SNS in the pons for depression treatment. Materials and methods: Two experiments were conducted. In Experiment 1, 32 rats were divided into four groups: (1) a Control (C) group that received distilled water as a vehicle; (2) a Model (M) group that received the chronic unpredictable mild stress (CUMS) procedure and was administered distilled water; (3) a Stress + SNS (MS) group that received the CUMS procedure and was administered SNS dissolved in distilled water; and (4) a Stress + Fluoxetine (MF) group that received the CUMS procedure and was administered fluoxetine dissolved in distilled water. The open field test (OFT), the sucrose preference test (SPT), and the novel object recognition test (NOR) were performed to test the antidepressant effects of SNS. High-throughput mRNA sequencing (RNA-seq) was used to explore possible gene targets of SNS in the pons, and quantitative real-time PCR was performed to verify the results. High-performance liquid chromatography was used to detect neurotransmitters. Finally, correlation analyses were conducted between behaviors, genes expression, and neurotransmitters. In Experiment 2, 18 rats were divided into the same three groups as in Experiment 1: (1) C, (2) M, and (3) MS. fMRI was used to confirm whether SNS altered the pons in a rat model of depression. Results: SNS significantly improved sucrose preference in the SPT and T-N-T-O in the NOR compared to the M group (P < 0.05). RNA-seq filtered 49 differentially expressed genes(DEGs) that SNS could reverse in the pons of the CUMS depression model. Real-time PCR detected six genes, including Complexin2 (Cplx2), Serpinf1, Neuregulin1 (Nrg1), Annexin A1 (Anxa1), beta-arrestin 1 (Arrb1) and presenilin 1 (Psen1). SNS significantly reversed changes in the expression of Anxa1, Nrg1, and Psen1 caused by CUMS (P < 0.05), which is consistent with the DEGs results. Additionally, SNS significantly reversed norepinephrine (NE) changes in the pons. There were 18 noteworthy correlations between behavior, genes, and neurotransmitters (P < 0.05). fMRI showed that SNS can decrease the amplitude of low-frequency fluctuations (ALFF) in the pons of living depressed rats. Conclusion: The pons is an important target brain region for SNS to exert its antidepressant effects. SNS may improve pontine NE levels by regulating the Anxa1, Nrg1, and Psen1 genes, thereby exerting antidepressant effects and improving cognitive function.
引用
收藏
页数:13
相关论文
共 46 条
  • [21] Li J., 2018, World J. Tradit. Chin. Med, V13, P2130, DOI [10.3969/j.issn.1673-7202.2018.09.008, DOI 10.3969/J.ISSN.1673-7202.2018.09.008]
  • [22] Effects of stress on behavior and resting-state fMRI in rats and evaluation of Telmisartan therapy in a stress-induced depression model
    Li, Junling
    Yang, Ran
    Xia, Kai
    Wang, Tian
    Nie, Binbin
    Gao, Kuo
    Chen, Jianxin
    Zhao, Huihui
    Li, Yubo
    Wang, Wei
    [J]. BMC PSYCHIATRY, 2018, 18
  • [23] Li T., 2005, Mod. Traditional Chin. Med. Materia Medica-World Sci. Technol, Vs1, P48
  • [24] SympGAN: A systematic knowledge integration system for symptom-gene associations network
    Lu, Kezhi
    Yang, Kuo
    Sun, Hailong
    Zhang, Qian
    Zheng, Qiguang
    Xu, Kuan
    Chen, Jianxin
    Zhou, Xuezhong
    [J]. KNOWLEDGE-BASED SYSTEMS, 2023, 276
  • [25] Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and Prospective
    Luo, Ting-ting
    Lu, Yuan
    Yan, Shi-kai
    Xiao, Xue
    Rong, Xiang-lu
    Guo, Jiao
    [J]. CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2020, 26 (01) : 72 - 80
  • [26] Depression
    Malhi, Gin S.
    Mann, J. John
    [J]. LANCET, 2018, 392 (10161) : 2299 - 2312
  • [27] Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice
    Martin-Sanchez, Ana
    Pinero, Janet
    Nonell, Lara
    Arnal, Magdalena
    Ribe, Elena M.
    Nevado-Holgado, Alejo
    Lovestone, Simon
    Sanz, Ferran
    Furlong, Laura I.
    Valverde, Olga
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [28] Where in the Brain Is Depression?
    Pandya, Mayur
    Altinay, Murat
    Malone, Donald A., Jr.
    Anand, Amit
    [J]. CURRENT PSYCHIATRY REPORTS, 2012, 14 (06) : 634 - 642
  • [29] Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
  • [30] The Role of Annexin A1 and Formyl Peptide Receptor 2/3 Signaling in Chronic Corticosterone-Induced Depression-Like Behaviors and Impairment in Hippocampal-Dependent Memory
    Peritore, Alessio Filippo
    Crupi, Rosalia
    Scuto, Maria
    Gugliandolo, Enrico
    Siracusa, Rosalba
    Impellizzeri, Daniela
    Cordaro, Marika
    D'amico, Ramona
    Fusco, Roberta
    Di Paola, Rosanna
    Cuzzocrea, Salvatore
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (01) : 27 - 43